187 related articles for article (PubMed ID: 19256534)
1. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
4. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
5. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
6. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
[TBL] [Abstract][Full Text] [Related]
7. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
Barb AW; Zhou P
Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
[TBL] [Abstract][Full Text] [Related]
9. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
[TBL] [Abstract][Full Text] [Related]
10. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
Coggins BE; Li X; McClerren AL; Hindsgaul O; Raetz CR; Zhou P
Nat Struct Biol; 2003 Aug; 10(8):645-51. PubMed ID: 12833153
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
12. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
[TBL] [Abstract][Full Text] [Related]
14. Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design.
Kalinin DV; Holl R
Curr Top Med Chem; 2016; 16(21):2379-430. PubMed ID: 27072691
[TBL] [Abstract][Full Text] [Related]
15. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
[TBL] [Abstract][Full Text] [Related]
16. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 1999 Feb; 38(6):1902-11. PubMed ID: 10026271
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activities and characterization of novel inhibitors of LpxC.
Clements JM; Coignard F; Johnson I; Chandler S; Palan S; Waller A; Wijkmans J; Hunter MG
Antimicrob Agents Chemother; 2002 Jun; 46(6):1793-9. PubMed ID: 12019092
[TBL] [Abstract][Full Text] [Related]
18. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
[TBL] [Abstract][Full Text] [Related]
19. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 2001 Jan; 40(2):514-23. PubMed ID: 11148046
[TBL] [Abstract][Full Text] [Related]
20. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]